Literature DB >> 8824650

Only four days of quadruple therapy can effectively cure Helicobacter pylori infection.

W A De Boer1, W M Driessen, G N Tytgat.   

Abstract

AIM: To determine whether 4 days of quadruple therapy using bismuth, tetracycline and metronidazole combined with omeprazole is effective treatment for Helicobacter pylori infection.
METHODS: Non-ulcer dyspepsia, as well as chronic peptic ulcer patients with biopsy-proven H. pylori infection received 4 days of quadruple therapy. They were pretreated with 3 days of omeprazole. At least 5-6 weeks later, endoscopy was repeated with 10 biopsies for urease test, histology and culture to establish cure of infection.
RESULTS: None of the 54 patients included was lost to follow-up but two had a 14C-urea breath test instead of endoscopy. Side-effects did not interfere with compliance. Forty-nine out of 54 patients (91%; 95% CI: 80-97%) were cured. Metronidazole susceptibility data were available from 43 pre-treatment isolates. Of these 38/40 (95%) with a metronidazole-sensitive strain, and one of three with a metronidazole-resistant strain were cured.
CONCLUSIONS: Four days of quadruple therapy after omeprazole pre-treatment is a feasible, well tolerated, and effective treatment for H. pylori infection, especially in those carrying a metronidazole-sensitive strain. It seems that in quadruple therapy, cure rate and treatment duration have a non-linear relation. Our results need confirmation, but for patients suffering from side-effects with the 7-day regimen stopping treatment after 4 days is justified.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8824650     DOI: 10.1111/j.1365-2036.1995.tb00432.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

Review 1.  Helicobacter pylori.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  2000-03       Impact factor: 2.401

2.  First-line therapy in Helicobacter pylori eradication therapy: experience of a surgical clinic.

Authors:  Gökhan Selçuk Özbalcı; Saim Savaş Yürüker; İsmail Alper Tarım; Hamza Çınar; Ayfer Kamalı Polat; Aysu Başak Özbalcı; Kağan Karabulut; Kenan Erzurumlu
Journal:  Ulus Cerrahi Derg       Date:  2014-09-01

3.  Eradication of Helicobacter pylori: the results of a pilot study of 3, 5 & 7 day triple antibiotic regime with bismuth for one month.

Authors:  H J O'Connor; K Cunnane; J S Collins; J M Sloan; B T Johnston; K C Bamford; J Gilvarry; C A O'Morain
Journal:  Ir J Med Sci       Date:  1997 Jan-Mar       Impact factor: 1.568

Review 4.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 5.  Helicobacter pylori.

Authors:  B E Dunn; H Cohen; M J Blaser
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

6.  Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.

Authors:  Mohammad Hassan Emami; Mohammad Mehdi Saberfiroozi; Abbas Arj; Ali Reza Taghavi; Kamran Bagheri-Lankarani; Najaf Dehbashi; Mohammad Reza Fattahi; Mahvash Alizadeh; Mohammad Javad Kaviani; Rahim Bahri-Najafi; Bita Geramizadeh; Abbas Esmaeili
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

Review 7.  Clinical relevance of resistant strains of Helicobacter pylori: a review of current data.

Authors:  F Mégraud; H P Doermann
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

Review 8.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 9.  Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship.

Authors:  Akiko Shiotani; Priya Roy; Hong Lu; David Y Graham
Journal:  Therap Adv Gastroenterol       Date:  2021-12-21       Impact factor: 4.409

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.